You are here

CAR-T Therapies Approved on a Case-by-Case

Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.

Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) cost $373,000 to treat adults with advanced lymphomas, while Kymriah costs $475,000 to treat acute lymphoblastic leukemia in children and young adults, according to Kaiser Health News. Many patients experience serious side effects require ICU care. Treatment costs can pile up to more than a $1 million.

However, most commercial insurers are covering CAR-T therapies, but they do so on an individual basis, writing single-patient agreements each time, cancer experts told KHN. And large insurers that are already familiar with complicated therapies like stem cell transplants are getting speedier at handling CAR-T treatment requests, the experts told news services. It is a different story with small or regional plans where approval can take weeks for patients who are fighting cancer after other treatments failed.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation